One year's treatment of paget's disease of bone by synthetic salmon calcitonin as a nasal spray

Open Access
Publisher Website
Google Scholar
Abstract
The effectiveness of synthetic salmon calcitonin (SCT) administered as a nasal spray was assessed via clinical, biological, and radiological variables in 17 previously untreated Pagetic patients over a 1-year course of therapy. The results showed a highly significant decrease of serum alkaline phosphatase (S-ALP) (p < 0.05 after 1 month of treatment) and of the urinary hydroxyproline/creatinine ratio (OH/Cr) (p < 0.01 after 1 month of treatment). For the whole group, the mean decrease in S-ALP was 37 ± 4% (SEM) after 6 months (p < 0.01) and 31 ± 5% after 1 year (p < 0.01). The mean fall in OH/Cr was 35 ± 6% (SEM) (p < 0.01) and 37 ± 7% (p < 0.01) after 6 and 12 months, respectively. None of the usual side-effects of SCT were reported and local tolerance was excellent throughout the study.